Documentos relacionados

1. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
2. Treatment discontinuation in older people with multiple sclerosis.
3. Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
4. Low-dose rituximab should be used for treating MS in resource-limited settings: No.
5. Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
6. Rituximab treatment for multiple sclerosis.
7. World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
8. Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
9. Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
10. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.